Fresenius Delivers Record Cash Generation but Shares Sink to Fresh Lows

The healthcare group Fresenius is caught in a curious stalemate: its operating metrics are strengthening, yet its stock keeps sliding. On Friday the shares touched a new 52-week low of €36.28, marking a 24.21% decline since the start of the year and sitting more than a fifth below their 200-day moving average. That slide came despite a first-quarter report that showed operating cash flow nearly quadrupled.

Operational momentum builds under the surface

Fresenius SE generated group revenue of €5.74 billion in the three months to March, with organic growth of 5%. Currency-adjusted EBIT rose 6% to €678 million, while core earnings per share climbed 13% to €0.82. The most striking figure was operating cash flow, which surged to €389 million from €100 million a year earlier — a fourfold increase that underscores improving working capital management and margin discipline.

The Kabi division, a longtime drag, posted organic growth of 6%, with its biopharma arm expanding at a 34% clip. That helped offset headwinds from the Ketosteril tender business in China, where pricing pressure in clinical nutrition continues to cloud sentiment. Net leverage improved to 2.6 times EBITDA, giving the balance sheet more breathing room.

FMC underwrites a €1 billion buyback

The dialysis subsidiary Fresenius Medical Care has rolled out a fresh share repurchase programme worth roughly €1 billion, spread over twelve months. It follows the successful conclusion of an earlier buyback and signals that the "FME Reignite" strategy — which hit its medium-term targets last year — is being used to return capital aggressively. Shareholders at FMC’s annual meeting in early May had already approved a dividend of €1.49 per share and authorised further repurchases.

Should investors sell immediately? Or is it worth buying Fresenius?

For the parent company, the annual meeting on 22 May cleared a dividend of €1.05 per share. Yet the broader market response has been tepid, with investors focusing less on the cash being returned and more on external risks.

Leadership ready for the next phase

Fresenius has also been fine-tuning its management team. The supervisory board extended CEO Michael Sen’s contract by five years, locking him in until 2031. Christian Pawlu, aged 48, will join the executive board on 1 July 2026 to take charge of the Helios and Quirónsalud hospital operations across Germany and Spain. The moves are intended to provide stability as the group navigates a tricky macro environment.

On the financing front, a €157 million Schuldschein tranche with a 4.40% coupon matured on Friday. The company stresses that it has ample headroom: around €2.8 billion in undrawn credit lines, consisting of a €2 billion syndicated facility and roughly €0.8 billion in bilateral commitments.

Outlook intact but market remains sceptical

Management continues to guide for 2026 organic revenue growth of 4–7%, a currency-adjusted core EPS increase of 5–10% and a target adjusted EBIT margin of around 11.5%. Those forecasts were reaffirmed with the first-quarter results, but the share price has brushed them aside.

Fresenius at a turning point? This analysis reveals what investors need to know now.

China remains the most visible overhang. Although Kabi and biopharma show strong momentum, the pricing pressure in clinical nutrition and the lingering effects of the Ketosteril tender mean that Fresenius cannot escape the scrutiny of investors wary of emerging-market risk.

With the stock now hovering at €36.28, a break below this level would open the path towards €35. Any positive news out of Beijing, however, could help close the gap between what the company delivers operationally and what its valuation reflects. Until then, Fresenius finds itself in a paradox that no amount of cash flow alone seems able to resolve.

Ad

Fresenius Stock: New Analysis - 31 May

Fresh Fresenius information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Fresenius analysis...

en | DE0005785604 | FRESENIUS | boerse | 69452415 |